Spring, Laura M.
Wander, Seth A.
Zangardi, Mark
Bardia, Aditya
Funding for this research was provided by:
National Cancer Institute (KL2 TR002542)
Article History
First Online: 26 February 2019
Compliance with Ethical Standards
:
: Laura M. Spring has received compensation from Novartis for service as a consultant and participation on advisory boards.Seth A. Wander has received compensation from Foundation Medicine and InfiniteMD for service as a consultant and from Eli Lilly for participation on advisory boards.Mark Zangardi declares that he has no conflict of interest.Aditya Bardia has received research funding (paid to his institution) from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Mersana Therapeutics, Innocrin, and Biotheranostics; has received compensation from Pfizer, Novartis, Genentech, Merck, Radius Health, and Immunomedics for service as a consultant and participation on advisory boards and steering committees; and has received compensation from Spectrum Pharmaceuticals and Taiho Pharmaceutical for service as a consultant and participation on advisory boards.
: This article does not contain any studies with human or animal subjects performed by any of the authors.